Gastroenteropancreatic (GEP) neuroendocrine neoplasms are classified as low‐grade,
intermediate‐grade, and high‐grade tumors based on morphologic criteria and the …

In 1983, a monoclonal antibody, Ki67, was generated, that labeled the nuclei of proliferating
non-neoplastic and neoplastic cells. The name Ki67 derived from the city of Kiel (Ki) where …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …

Only advances that occurred from 2011 to 2014 that either strengthen the previous 2011
guidelines [1, 2] or lead to changes or additional guidelines are reviewed here. Advances …

The WHO 2010 classification [1] distinguishes between well-differentiated neuroendocrine
tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) of small or …

Data on gastroenteropancreatic neuroendocrine neoplasms (NEN) G3 (well-differentiated
neuroendocrine tumors (NET G3) and neuroendocrine carcinoma (NEC)) are limited. We …

Human pancreatic tumor cell lines–AsPC-1, PANC-1, MIA paca2, KP-1 and KP-59 cells–can
be induced to differentiate into pancreatic hormone-producing cells by brief trypsin treatment …

Abstract In 2010, the World Health Organization (WHO) classification of neuroendocrine
neoplasms was reviewed and validated the crucial role of the proliferative rate. According to …

Neuroendocrine tumors comprise a broad family of tumors, the most common of which are
carcinoid and pancreatic neuroendocrine tumors. The NCCN Neuroendocrine Tumors …

Purpose The European Neuroendocrine Tumor Society (ENETS) and the American Joint
Committee on Cancer (AJCC) staging classifications are two widely used systems in …